CYBB-edited autologous CD34-positive hematopoietic stem cell therapy (MaxCyte/NIH)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCYBB-edited autologous CD34-positive hematopoietic stem cell therapy (MaxCyte/NIH)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCYBB gene stimulants
TargetsNADPH Oxidase 2
Therapy Area/IndicationsGranulomatous Disease, ChronicAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMaxcyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthMaxcyte Inc
Active IndicationsN/A
Inactive IndicationsGranulomatous Disease, ChronicAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A